Article
A normal genetic variation modulates synaptic MMP-9 protein levels and the severity of schizophrenia symptoms.
EMBO molecular medicine - 1 Aug 2017
Lepeta Katarzyna, Purzycka Katarzyna J, Pachulska-Wieczorek Katarzyna, Mitjans Marina, Begemann Martin, Vafadari Behnam, Bijata Krystian, Adamiak Ryszard W, Ehrenreich Hannelore, Dziembowska Magdalena, Kaczmarek Leszek
Abstract excerpt
Matrix metalloproteinase 9 (MMP-9) has recently emerged as a molecule that contributes to pathological synaptic plasticity in schizophrenia, but explanation of the underlying mechanisms has been missing. In the present study, we performed a phenotype-based genetic association study (PGAS) in > 1,000 schizophrenia patients from the Göttingen Research Association for Schizophrenia (GRAS) data collection and found...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.